The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

Stocks•18 April 2026•

1 min read

CAMP4 Therapeutics Short Interest Drops Despite Significant Earnings Miss

Key Facts

1Short interest for CAMP4 decreased by 14.2% in March to 414,235 shares.

2The company reported an EPS loss of ($0.87), significantly missing the expected ($0.31).

3Analysts maintain a 'Moderate Buy' rating with an average price target of $8.60.

CAMP4 Therapeutics Corporation (NASDAQ: CAMP) saw a significant 14.2% decline in short interest during March, with total shorted shares falling to 414,235. This reduction in selling pressure occurred despite the company reporting a substantial earnings miss for the quarter. CAMP4 posted an EPS loss of $0.87, which was significantly wider than the consensus estimate of a $0.31 loss. Nevertheless, the analyst community remains relatively optimistic, maintaining a "Moderate Buy" rating on the stock. The average price target for the biotech firm currently stands at $8.60. This mix of technical short-covering and fundamental financial headwinds suggests a complex outlook for investors. Market participants are now focusing on whether the company can stabilize its bottom line in the coming quarters.